

DESCRIPTION


<i>Description</i>	Recombinant Human Coronavirus SARS-CoV-2 Spike Protein S1 subunit, Receptor-Binding Domain (RBD), variant Mu, Lineage B.1.621 (21H, Colombia)
<i>Sequence</i>	Native NCBI Accession Number: MN908947, Arg319-Phe541, with mutations R346K; E484K; N501Y
<i>Expression system</i>	HEK293 cells
<i>Tag</i>	HIS Tag C-Terminus
<i>Purification</i>	Affinity chromatography
<i>Extinction coefficient</i>	35340 M ⁻¹ .cm ⁻¹ Abs 0.1% (=1 g/l) 1.35 assuming all pairs of Cys residues form cystines
<i>Predicted Molecular Weight</i>	26 kDa

SPECIFICATIONS

<i>SDS Page</i>	Approx. 32 kDa
<i>Concentration</i>	1 mg/ml
<i>Purity</i>	>90% by SDS PAGE gel
<i>Formulation</i>	Liquid PBS
<i>Activity</i>	Recognized by CR3022 anti RBD recombinant antibody
<i>Stability and Storage</i>	Store at minimum -20°C. Avoid repeated freeze-thaw cycles

DATA

SDS-PAGE 4-15% under reducing conditions and visualized by Coomassie blue staining showing a band at approx. 33 kDa	Western Blot: RBD Variant Mu HIS Tag detected with anti-HIS-Tag antibody HRP conjugate showing a band at approx. 33 kDa
---	---



SARS-CoV-2 Spike Glycoprotein (S1) RBD variant Mu Lineage B.1.621

Spike protein (S protein) is one of the four structural proteins of Coronavirus (SARS-Cov, SARS-Cov-2, MERS amongst others), S protein plays the most important role in viral attachment, fusion, and entry, and it serves as a target for development of antibodies, entry inhibitors and vaccines.

In the S protein, the Receptor Binding Domain (RBD) mediates viral entry of SARS-Cov and SARS-Cov-2 into host cells by its interaction with the membrane receptor ACE2 (Angiotensin-converting enzyme 2).

The variant lineage B.1.621 of SARS-Cov-2 was first identified early in 2021 in samples collected in South America, predominantly in Colombia.

Named the variant Mu, it is the fifth "variant of interest" to be monitored by WHO since March 2021. It presents 3 mutations (R346K; E484K; N501Y) that suggest it may be more resistant to vaccines and/or previous infections.

Products Manufactured and Distributed by:

Diacclone SAS – Part of Medix Biochemica Group

6 Rue Dr Jean-François-Xavier Girod

BP 1985, 25020 Besançon Cedex

France

Tel +33 (0)3 81 41 38 38 Fax +33 (0)3 81 41 36 36

Email: info@diacclone.com www.diacclone.com

Rec SARS-CoV-2 RBD variant Mu Lineage B.1.621 715-H26-0BU

Version 1 01/2022